MARC Record from marc_columbia

LEADER: 05233pam a22004454a 4500
001 5506086
005 20221121180147.0
008 050808t20062006paua b 001 0 eng
010 $a 2005022888
016 7 $a101254564$2DNLM
020 $a0781756286 (alk. paper)
029 1 $aNLM$b101254564
035 $a(OCoLC)ocm61285522
035 $a(NNC)5506086
035 $a5506086
040 $aDNLM/DLC$cDLC$dYDX$dNLM$dBAKER$dOrLoB-B
042 $apcc
050 00 $aRC271.C5$bC32219 2006
060 00 $a2005 N-986
060 10 $aQZ 267$bC21515 2006
082 00 $a616.99/4061$222
245 00 $aCancer chemotherapy and biotherapy :$bprinciples and practice /$ceditors Bruce A. Chabner, Dan L. Longo.
250 $a4th ed.
260 $aPhiladelphia :$bLippincott Williams & Wilkins,$c[2006], ©2006.
300 $axv, 879 pages :$billustrations (some color) ;$c29 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $g1.$tClinical strategies for cancer treatment : the role of drugs /$rBruce A. Chabner -- $g2.$tPreclinical aspects of cancer drug discovery and development /$rPaula Krosky, Melinda Hollingshead, Robert Shoemaker and Edward A. Sausville -- $g3.$tPharmacokinetics /$rJerry Collins and Jeffrey G. Supko -- $g4.$tInfertility after cancer chemotherapy /$rAngela Bradbury and Richard L. Schilsky -- $g5.$tCarcinogenesis of anticancer drugs /$rLawrence S. Blaszkowsky and Charles Erlichman -- $g6.$tAntifolates /$rBrian P. Monahan and Carmen J. Allegra -- $g7.$t5-fluoropyrimidines /$rJean L. Grem -- $g8.$tCytidine analogues /$rDavid P. Ryan, Rocio Garcia-Carbonero and Bruce A. Chabner -- $g9.$tPurine antimetabolites /$rKenneth R. Hande -- $g10.$tHydroxyurea /$rLuis Paz-Ares, Ross C. Donehower and Bruce A. Chabner -- $g11.$tAntimicrotubule agents /$rEric K. Rowinsky -- $g12.$tClinical and high-dose alkylating agents /$rKenneth D. Tew, O. Michael Colvin and Roy B. Jones -- $g13.$tNonclassic agents /$rHenry S. Friedman, Steven D. Averbuch and Joanne Kurtzberg -- $g14.$tCisplatin, carboplatin, and oxaliplatin /$rEddie Reed -- $g15.$tBleomycin /$rJohn S. Lazo and Bruce A. Chabner -- $g16.$tAntitumor antibiotics /$rEdwin W. Willems, Kees Nooter and Jaap Verweij -- $g17.$tTopoisomerase I-targeting drugs /$rAlex Sparreboom and William C. Zamboni -- $g18.$tAnthracyclines and anthracenediones /$rJames H. Doroshow -- $g19.$tTopoisomerase II inhibitors : the epipodophyllotoxins, acridines, and ellipticines /$rYves Pommier and Francois Goldwasser -- $g20.$tAsparaginase /$rBruce A. Chabner and Alison M. Friedmann -- $g21.$tDelivering anticancer drugs to brain tumors /$rMaciej M. Mrugala, Tracy T. Batchelor and Jeffrey C. Supko -- $g22.$tFood and drug administration role in oncology product development /$rThomas G. Roberts, Jr. -- $g23.$tCentral venous catheters : care and complications /$rRachel P. Rosovsky and David J. Kuter -- $g24.$tPharmacogenetics /$rJeanne Fourie and Robert B. Diasio -- $g25.$tNew targets for anticancer therapeutics /$rA. Dimitrios Colevas, Orit Scharf, Janet E. Dancey, S. Percy Ivy, Len Neckers, Bennett Kaufman and Richard Swerdlow -- $g26.$tBisphosphonates /$rMatthew R. Smith -- $g27.$tThalidomide and its analogs for the treatment of hematologic malignancies, including multiple myeloma, and solid tumors /$rPaul Richardson, Constantine S. Mitsiades, Teru Hideshima and Kenneth Anderson -- $g28.$tInhibitors of tumor angiogenesis /$rAnaadriana Zakarija and William I. Gradishar -- $g29.$tProteasome inhibitors /$rOwen A. O'Connor -- $g30.$tMolecular targeted drugs and growth factor receptor inhibitors /$rJeffrey W. Clark -- $g31.$tAntibody therapies of cancer /$rDavid A. Scheinberg, Deborah A. Mulford, Joseph G. Juric, Richard P. Junghans and George Sgouros -- $g32.$tInterferons /$rDaniel J. Lindner, Kevin L. Taylor, Frederic J. Reu, Paul A. Masci and Ernest C. Borden -- $g33.$tAdoptive cellular therapies /$rCarl H. June -- $g34.$tCancer vaccines /$rGlenn Dranoff -- $g35.$tHematopoietic growth factors /$rWilliam P. Petros -- $g36.$tInterleukins /$rGheath Alatrash, Ronald M. Bukowski, Charles S. Tannenbaum and James H. Finke -- $g37.$tHormonal therapy for breast cancer /$rPeter F. Lebowitz and Sandra M. Swain.
650 0 $aCancer$xChemotherapy.$0http://id.loc.gov/authorities/subjects/sh85019497
650 0 $aCancer$xImmunotherapy.$0http://id.loc.gov/authorities/subjects/sh87002642
650 0 $aAntineoplastic agents.$0http://id.loc.gov/authorities/subjects/sh85005714
650 0 $aBiological response modifiers.$0http://id.loc.gov/authorities/subjects/sh85014187
650 12 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 22 $aAntineoplastic Agents$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000970Q000627
650 22 $aBiological Factors$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D001685Q000627
700 1 $aChabner, Bruce.$0http://id.loc.gov/authorities/names/n81094702
700 1 $aLongo, Dan L.$q(Dan Louis),$d1949-$0http://id.loc.gov/authorities/names/n95802899
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip0517/2005022888.html
852 00 $boff,hsl$hRC271.C5$iC32219 2006 Q